共 73 条
[1]
Saginala K(2020)Epidemiology of bladder cancer Med Sci (Basel) 8 15-1029
[2]
Barsouk A(2016)Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline J Urol 196 1021-1194
[3]
Aluru JS(2021)Immune checkpoint inhibitors for the treatment of bladder cancer Cancers (Basel) 13 131-3064
[4]
Rawla P(2021)Boosting bladder cancer treatment by intravesical nitazoxanide and bacillus calmette-guérin association World J Urol 39 1187-537
[5]
Padala SA(2017)Intravesical Thalidomide boosts bacillus Calmette–Guérin (BCG) in non-muscle invasive bladder cancer treatment Med Oncol 35 3-603
[6]
Barsouk A(2008)Targeting Akt/Mtor and Erk Mapk signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model J Clin Invest 118 3051-689
[7]
Chang SS(2005)mTOR-targeted therapy of cancer with rapamycin derivatives Ann Oncol 16 525-153
[8]
Boorjian SA(2017)Intravesical BCG induces CD4+ T cell expansion in an immune competent model of bladder cancer Cancer Immunol Res 5 594-3813
[9]
Chou R(2015)Intravesical bacillus Calmette–Guérin efficiently reduces p70S6K1 but not 4E-BP1 phosphorylation in nonmuscle invasive bladder cancer J Urol 193 682-1076
[10]
Lopez-Beltran A(2005)The 2004 WHO classification of bladder tumors: a summary and commentary Int J Surg Pathol 13 143-21